NAICS Code 325413-01 - In-Vitro/In-Vivo Diagnostic Sbstnc (Manufacturing)

Marketing Level - NAICS 8-Digit

Business Lists and Databases Available for Marketing and Research

Total Verified Companies: 177
Contact Emails: 8,142
Company Websites: 163
Phone Numbers: 125
Business Addresses: 177
Companies with Email: 143
Get Business List
NAICS CODE 325413-01
Reach new customers, connect with decision makers, and grow your business.
Pricing from $0.05 to $0.25 per lead
Ideal for: Direct Mailing Email Campaigns Calling Market Research ‐ Free Sample & Report, Custom Lists, and Expert Support — All Included
Looking for more companies? See NAICS 325413 - In-Vitro Diagnostic Substance Manufacturing - 177 companies, 8,142 emails.

NAICS Code 325413-01 Description (8-Digit)

The In-Vitro/In-Vivo Diagnostic Substance Manufacturing industry involves the production of substances used for diagnostic purposes in both in-vitro and in-vivo settings. In-vitro diagnostic substances are used to diagnose diseases and conditions through the analysis of samples taken from the body, such as blood or urine. In-vivo diagnostic substances are used to visualize and diagnose conditions within the body, such as through medical imaging. This industry plays a crucial role in the healthcare sector by providing healthcare professionals with the tools necessary to accurately diagnose and treat patients. The manufacturing process for in-vitro/in-vivo diagnostic substances involves a range of complex procedures, including chemical synthesis, purification, and formulation. Quality control is of utmost importance in this industry, as the accuracy of diagnostic tests relies on the purity and consistency of the substances produced. The industry is heavily regulated by government agencies to ensure that products meet strict safety and efficacy standards. The demand for in-vitro/in-vivo diagnostic substances is driven by the prevalence of diseases and conditions that require diagnostic testing, as well as advancements in medical technology that allow for more accurate and efficient testing methods. The industry is expected to continue to grow as the global population ages and the prevalence of chronic diseases increases.

Parent Code - Official US Census

Official 6‑digit NAICS codes serve as the parent classification used for government registrations and documentation. The marketing-level 8‑digit codes act as child extensions of these official classifications, providing refined segmentation for more precise targeting and detailed niche insights. Related industries are listed under the parent code, offering a broader context of the industry environment. For further details on the official classification for this industry, please visit the U.S. Census Bureau NAICS Code 325413 page

Tools

Tools commonly used in the In-Vitro/In-Vivo Diagnostic Sbstnc (Manufacturing) industry for day-to-day tasks and operations.

  • Chromatography systems
  • Mass spectrometers
  • Liquid handling systems
  • Microplate readers
  • Electrophoresis systems
  • PCR machines
  • Microscopes
  • Imaging equipment
  • Centrifuges
  • Spectrophotometers
  • NMR machines
  • Flow cytometers
  • Microfluidic devices
  • Bioreactors
  • Freeze dryers
  • Lyophilizers
  • Autoclaves
  • Incubators
  • Microarray scanners
  • Microtomes

Industry Examples of In-Vitro/In-Vivo Diagnostic Sbstnc (Manufacturing)

Common products and services typical of NAICS Code 325413-01, illustrating the main business activities and contributions to the market.

  • Diagnostic reagents
  • Contrast agents
  • Radiopharmaceuticals
  • Blood glucose test strips
  • Pregnancy test kits
  • HIV test kits
  • Cancer biomarker tests
  • Allergy testing kits
  • Blood typing reagents
  • Coagulation reagents
  • Microbial identification kits
  • Urine analysis reagents
  • Fecal occult blood test kits
  • Cardiac marker tests
  • Tumor marker tests
  • Infectious disease tests
  • Genetic testing kits
  • Hormone assays
  • Immunohistochemistry reagents

History

A concise historical narrative of NAICS Code 325413-01 covering global milestones and recent developments within the United States.

  • The In-Vitro/In-Vivo Diagnostic Sbstnc (Manufacturing) industry has a long history of advancements and milestones. In 1952, Rosalind Franklin discovered the structure of DNA, which led to the development of diagnostic tests for genetic diseases. In 1960, the first enzyme-linked immunosorbent assay (ELISA) was developed, which allowed for the detection of small amounts of antigens or antibodies in a sample. In 1983, the first HIV test was approved by the FDA, which revolutionized the diagnosis and treatment of the disease. In recent history, the industry has seen advancements in personalized medicine, with the development of companion diagnostics that can identify patients who are most likely to benefit from a particular treatment. Additionally, the industry has seen an increase in the use of point-of-care testing, which allows for rapid diagnosis and treatment of patients in remote or underserved areas. In the United States, the In-Vitro/In-Vivo Diagnostic Sbstnc (Manufacturing) industry has seen significant growth in recent years. In 2019, the industry generated $25.5 billion in revenue, up from $22.7 billion in 2015. This growth can be attributed to several factors, including an aging population, an increase in chronic diseases, and advancements in technology. The industry has also seen an increase in mergers and acquisitions, with larger companies acquiring smaller ones to expand their product offerings and increase their market share. Overall, the In-Vitro/In-Vivo Diagnostic Sbstnc (Manufacturing) industry has a rich history of advancements and continues to play a critical role in the diagnosis and treatment of diseases worldwide.